HPV leaves its mark in oropharyngeal squamous cell carcinoma

May 1, 2013

Oropharyngeal squamous cell carcinoma (OPSCC) is a form of cancer that affects the cells lining the middle part of the throat, including the soft palate, the base of the tongue, the tonsils, and the pharynx.

High-risk types of (HPV) are increasingly detected in patients with OPSCC; however, HPV-positive OPSCC is highly curable and patients with HPV have better survival compared to HPV-negative patients, whose cancers are usually associate with alcohol and tobacco use.

To understand the molecular mechanisms underlying these differences, Jochen Hess and colleagues at University Hospital Heidelberg in Heidelberg, Germany monitored changes in DNA modifications in HPV-positive and HPV-negative OPSCCs.

In this issue of the Journal of Clinical Investigation, they identified a specific pattern of DNA modification that is dependent on the presence of HPV. This DNA modification pattern was significantly correlated with improved survival in three separate groups of OPSCC patients. This study identifies a specific cellular alteration that can predict clinical outcomes for patients with OPSCC.

Explore further: HPV improves survival for African-Americans with throat cancer

More information: HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas, J Clin Invest. doi:10.1172/JCI67010

Related Stories

HPV improves survival for African-Americans with throat cancer

March 28, 2013
Even though the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with throat cancer, according ...

HPV improves survival for African-Americans with throat cancer

July 19, 2012
Even though the human papillomavirus (HPV) is a risk factor for certain head and neck cancers, its presence could make all the difference in terms of survival, especially for African Americans with throat cancer, say Henry ...

In oropharyngeal cancer, HPV status impacts distant mets risk

January 14, 2013
(HealthDay)—In patients with oropharyngeal cancer (OPC), human papillomavirus (HPV) status and T and N staging categories affect the rate of distant control (DC) and may help identify candidates for treatment deintensification ...

Gender, insurance type tied to HPV infection in laryngeal cancer patients

September 14, 2011
The human papillomavirus (HPV) is more likely to be found in tumors of laryngeal cancer patients who are male and those with private health insurance, according to a new study from researchers at Henry Ford Hospital.

Recommended for you

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

Using artificial intelligence to improve early breast cancer detection

October 17, 2017
Every year 40,000 women die from breast cancer in the U.S. alone. When cancers are found early, they can often be cured. Mammograms are the best test available, but they're still imperfect and often result in false positive ...

New assay may boost targeted treatment of non-Hodgkin lymphoma

October 17, 2017
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.